Pacibekitug Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Pacibekitug Growth

(1) Massive ASCVD market opportunity with high residual inflammatory burden

Cardiovascular disease remains the leading cause of death globally. According to the WHO, nearly 17.9 million deaths annually are attributed to cardiovascular disease. Even with statins and newer lipid-lowering drugs, many patients continue to have elevated inflammatory markers such as hs-CRP, creating a major residual risk segment.

The landmark CANTOS trial (published in NEJM) showed that targeting inflammation via IL-1B inhibition reduced major adverse cardiovascular events, validating inflammation as a commercial target. Pacibekitug directly targets IL-6, which sits further downstream and may offer broader clinical utility.

(2) Strong Phase II efficacy data significantly de-risks the asset

In May 2025, Tourmaline Bio announced positive topline data from the Phase II TRANQUILITY trial:

• >85% reduction in hs-CRP at 15 mg monthly dosing
• >86% reduction in hs-CRP at 50 mg quarterly dosing
• p<0.0001 across all treatment arms vs placebo
• Adverse event rates were comparable to placebo

These results are highly meaningful because hs-CRP is a validated biomarker of residual inflammatory cardiovascular risk.

(3) First IL-6 inhibitor with quarterly dosing advantage

A major differentiator is convenience. Pacibekitug became the first IL-6 inhibitor to demonstrate deep inflammatory reduction with once-quarterly dosing.

This is important because chronic cardiovascular drugs require strong adherence. A once-every-3-month injection could be highly attractive compared with frequent biologic dosing schedules, particularly in large chronic-care populations.

(4) Backing from Novartis validates commercial potential

In September 2025, Novartis announced its acquisition of Tourmaline Bio for approximately $1.4 billion, specifically to acquire pacibekitug.

Novartis stated the asset is already "Phase III-ready", significantly improving commercialization probability due to:

• Large cardiovascular commercial infrastructure
• Global launch capabilities
• Strong payer negotiation power
• Faster development execution

Pacibekitug Recent Developments

In September 2025, Novartis announced that it entered into an agreement to acquire Tourmaline Bio, Inc. ("Tourmaline"), a New York-based, publicly traded clinical-stage biopharmaceutical company focused on developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease. Pacibekitug complements Novartis' cardiovascular strategy by targeting IL-6, a key upstream cytokine that promotes systemic inflammation, thus addressing a critical unmet need. With Phase II trials already well advanced, Novartis will acquire a Phase III ready asset which will complement its existing cardiovascular disease portfolio.

"Pacibekitug Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Pacibekitug for potential indication like Cardiovascular disorders, Graves ophthalmopathy, Kidney disorders and Abdominal aortic aneurysm in the 7MM. A detailed picture of Pacibekitug's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Pacibekitug for potential indications. The Pacibekitug market report provides insights about Pacibekitug's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Pacibekitug performance, future market assessments inclusive of the Pacibekitug market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Pacibekitug sales forecasts, along with factors driving its market.

Pacibekitug Drug Summary

Pacibekitug is an investigational, long-acting fully human IgG2 monoclonal antibody developed by Tourmaline Bio, Inc. that selectively binds to and neutralizes Interleukin-6 signaling, a key inflammatory cytokine implicated in cardiovascular, autoimmune, and inflammatory diseases. Designed for low-volume subcutaneous administration with potential quarterly dosing due to its extended half-life, pacibekitug aims to provide durable suppression of systemic inflammation while improving patient convenience compared with more frequently dosed IL-6 inhibitors. The drug was originally developed by Pfizer Inc. for autoimmune conditions such as Crohn's Disease and Systemic Lupus Erythematosus, and has since been repositioned for indications including Chronic Kidney Disease with elevated inflammation, atherosclerotic cardiovascular disease, and Thyroid Eye Disease. Early clinical studies have shown meaningful reductions in inflammatory biomarkers such as hs-CRP with a favorable safety profile, supporting its continued late-stage development as a differentiated anti-inflammatory therapy. The report provides Pacibekitug's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Pacibekitug Market Report

The report provides insights into:

• A comprehensive product overview including the Pacibekitug MoA, description, dosage and administration, research and development activities in potential indication like Cardiovascular disorders, Graves ophthalmopathy, Kidney disorders and Abdominal aortic aneurysm.
• Elaborated details on Pacibekitug regulatory milestones and other development activities have been provided in Pacibekitug market report.
• The report also highlights Pacibekitug's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Pacibekitug market report also covers the patents information, generic entry and impact on cost cut.
• The Pacibekitug market report contains current and forecasted Pacibekitug sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Pacibekitug market report also features the SWOT analysis with analyst views for Pacibekitug in potential indications.

Methodology:

The Pacibekitug market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Pacibekitug Analytical Perspective by DelveInsight

• In-depth Pacibekitug Market Assessment

This Pacibekitug sales market forecast report provides a detailed market assessment of Pacibekitug for potential indication like Cardiovascular disorders, Graves ophthalmopathy, Kidney disorders and Abdominal aortic aneurysm in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Pacibekitug sales data uptil 2034.

• Pacibekitug Clinical Assessment

The Pacibekitug market report provides the clinical trials information of Pacibekitug for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Pacibekitug Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Pacibekitug Market Potential & Revenue Forecast

• Projected market size for the Pacibekitug and its key indications
• Estimated Pacibekitug sales potential (Pacibekitug peak sales forecasts)
• Pacibekitug Pricing strategies and reimbursement landscape

Pacibekitug Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Pacibekitug Market positioning compared to existing treatments
• Pacibekitug Strengths & weaknesses relative to competitors

Pacibekitug Regulatory & Commercial Milestones

• Pacibekitug Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Pacibekitug Clinical Differentiation

• Pacibekitug Efficacy & safety advantages over existing drugs
• Pacibekitug Unique selling points

Pacibekitug Market Report Highlights

• In the coming years, the Pacibekitug market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Pacibekitug companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Pacibekitug's dominance.
• Other emerging products for Cardiovascular disorders, Graves ophthalmopathy, Kidney disorders and Abdominal aortic aneurysm are expected to give tough market competition to Pacibekitug and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Pacibekitug in potential indications.
• Analyse Pacibekitug cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Pacibekitug sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Pacibekitug in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Pacibekitug? How strong is Pacibekitug's clinical and commercial performance?
• What is Pacibekitug's clinical trial status in each individual indications such as Cardiovascular disorders, Graves ophthalmopathy, Kidney disorders and Abdominal aortic aneurysm and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Pacibekitug Manufacturers?
• What are the key designations that have been granted to Pacibekitug for potential indications? How are they going to impact Pacibekitug's penetration in various geographies?
• What is the current and forecasted Pacibekitug market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Pacibekitug in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Pacibekitug for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Pacibekitug? What is the duration of therapy and what are the geographical variations in cost per patient?